Electroporation Enhances Bleomycin Efficacy in Cats with Periocular Carcinoma and Advanced Squamous Cell Carcinoma of the Head

E.P. Spugnini, M. Pizzuto, M. Filippioni, L. Romani, B. Vincenzi, F. Menicagli, A. Lanza, R. De Girolamo, R. Lomonaco, M. Fanciulli, G. Spriano, and A. Baldi

**Background:** Advanced carcinoma of the head represents a substantial health problem in cats for local control and overall survival.

**Objectives:** Evaluate the capability of electrochemotherapy (ECT) to improve bleomycin efficacy in cats with periocular carcinoma and advanced carcinoma of the head.

**Animals:** Twenty-one cats with periocular carcinoma (17 squamous cell carcinoma [SCC] and 4 anaplastic carcinoma) and 26 cats with advanced SCC of the head.

**Methods:** Nonrandomized prospective controlled study. Periocular carcinoma cohorts: 12 cats were treated with bleomycin (15 mg/m² IV) coupled with ECT under anesthesia; 9 cats were treated with bleomycin alone. Advanced head SCC cohorts: 14 cats were treated with bleomycin (15 mg/m² IV) coupled with ECT administered under sedation; 12 control cats were treated with bleomycin alone. ECT treatments (2–8) were performed every other week until complete remission (CR) or tumor progression occurred.

**Results:** Toxicities were minimal and mostly treated symptomatically. Overall response rate in the ECT treated animals was 89% (21 Complete Response [CR] and 2 Partial Response [PR]) whereas controls had response rate of 33% (4 CR and 3 PR). Median time to progression in ECT group was 30.5 months, whereas in controls it was 3.9 months (P < .0001). Median time to progression for ECT cohorts was 24.2 months for periocular cohort and 20.6 in advanced head SCC cohort, respectively.

**Conclusions:** Electrochemotherapy is well tolerated for advanced SCC of the head in cats; its use may be considered among loco-regional strategies for cancer therapy in sensitive body regions such as periocular region.

**Key words:** Biphasic Pulses; Carcinoma; Electroporation; Feline.

Companion animals are largely protected from the carcinogenic effects of ultraviolet light by their haircoat and dermal pigmentation. However, animals with pale skin and hair color are at increased risk of solar injury. The 2 most prevalent neoplastic lesions induced by ultraviolet irradiation are cutaneous squamous cell carcinoma (SCC) in dogs and cats, and cutaneous hemangiosarcoma. Cutaneous carcinomas originate from epidermal stem cells that have the potential for self-renewal and multi-lineage differentiation; these cells are located in the hair follicle bulge and the basal layer of the interfollicular epidermis. Depending on the study, cutaneous carcinomas account, for approximately 15–50% of all cutaneous tumors in cats, making it among the 4 most common skin tumors in cats. These tumors frequently have an insidious progression characterized by nonhealing scabbing lesions on the eyelids, nasal planum or ears of light-colored cats that tend to progress over time to ulcers. These tumors are difficult to treat in a traditional clinical setting because of their advanced stage at time of presentation. As a result, these tumors that could be handled in their initial stages by surgery, cryotherapy or radiation therapy, require aggressive surgery combined with radiation therapy. In patients with advanced disease, aggressive surgery may compromise the cosmetic appearance of the cat. On the other hand, radiation therapy, when delivered to periorbital areas, such as the oral cavity or nose, sometimes has been associated with adverse ocular effects such as conjunctivitis, ulcerative keratitis and keratoconjunctivitis sicca. Electrochemotherapy has been gaining popularity among veterinary oncologists over the past several years and currently is adopted in human oncology as well. It aims at improving the efficacy of chemotherapy agents such as bleomycin or cisplatin by increasing their uptake into tumor cells by the administration of...
permeabilizing electric pulses. This technique has been used successfully in cats to treat nasal planum carcinoma and as an adjuvant for the treatment of incompletely excised soft tissue sarcoma, obtaining a high percentage of responses as well as long term control. Its use in the head region has been limited to date both in veterinary and human oncology because of concern for possible adverse effects for the eye and risk of massive tumor lysis. Indeed, tear production could act as a facilitator for the delivery of electric pulses and in some cases result in the re-routing of current flow along the lines of least electrical resistance with potential secondary damage to the lens, the retina or both. Patients also are risk for tumor lysis and fatal complications associated with rapidly shrinking tumors masses after ECT treatments. Finally, larger tumors may have areas of necrosis or extensive fibrosis that could impede smooth electrical transition during treatment. The goals of this study were to compare ECT associated with bleomycin versus bleomycin alone to evaluate for increased drug efficacy and lack of adverse effects (both local and systemic) after the administration of permeabilizing electric pulses in 2 cohorts of cats with periocular carcinomas and advanced SCC of the head.

Materials and Methods

**Animals**

Twenty-one feral colony cats or cats owned in rural areas with periocular carcinoma (17 squamous cell carcinoma [SCC] and 4 anaplastic carcinoma) were included in the periocular cohort and 26 were enrolled in the advanced head SCC cohort. The tumors in these cohorts were presumed to be UV-induced. Registered volunteer associations provided follow-up and transportation for the cats.

**Study Design**

The study was a controlled prospective nonrandomized trial matching a currently adopted systemic bleomycin-based protocol versus the same protocol with standard electroporation in cats with periocular carcinoma and advanced SCC of the head.

**Inclusion Criteria**

Cats were enrolled in the study if they fulfilled the following characteristics: a histopathologically confirmed diagnosis of ≥ T3 periocular carcinoma and advanced SCC of the head (Table 1); absence of distant metastases (lymph node metastases were not considered as exclusion factor); compliance of the owner for follow-up re-evaluation; absence of life-threatening diseases and overall performance status assessed according to the modified Karnovsky system of < 321. Cats with SCC localized to the oral cavity were not included in this study.

**Patient Staging**

All patients were staged by complete physical examination. A fine needle aspiration of mandibular lymph nodes, if palpable, was performed. Of the 47 cats enrolled in the study, 28 had both submandibular lymph nodes aspirated; 11 had the right lymph node and 8 had the left lymph node aspirated. Complete blood cell count, biochemistry profile, urinalysis, thoracic radiographs (projections) and abdominal ultrasonography also were performed. To confirm the diagnosis, histological examination of the biopsy samples was performed following standard protocols, using ematoxylin and eosin and ematoxylin and Van Gieson stains. All patients were treated with bleomycin systemically, ECT was additionally offered to the owners to be performed weekly under general anesthesia until CR or tumor progression was observed. In the periocular cohort, 12 owners elected for their cats to be treated with ECT whereas 9 others declined to pursue further treatment beyond standard iv. chemotherapy because of emotional or financial concerns. The tumor types were distributed as follows: 10 SCC patients and 2 anaplastic carcinoma patients were assigned to bleomycin and ECT treatment and 7 SCC patients and 2 anaplastic carcinoma patients were assigned to bleomycin treatment alone. Similarly, in the advanced head SCC cohort, 14 owners chose bleomycin and ECT, whereas 12 chose bleomycin alone. Both treatments were performed on alternate weeks and continued until CR or tumor progression was observed. However, upon reaching a maximum accumulation dose of 200 mg/m² the drug was discontinued. The total dose was exceeded in a single cat upon request of the owner. Complete blood cell count, biochemistry profile and urinalysis were performed during staging and before each therapy. Thoracic radiographs were taken at 1’s, 3’s, 5’s, 7’s, 9’s, 12’s and 18 months after the first IV therapy.

**Treatment Procedures**

Bleomycin was diluted in 5 mL of saline solution and administered IV at a dosage of 15 mg/m². In the ECT group, 5 minutes after the administration of the bleomycin, sequences of 8 biphasic electric pulses lasting 50 ± 50 ms each, with a frequency of 1 Hz, and with 1-ms interpulse intervals (total treatment time: 7.1 ms/cm² of treated area), were generated by a Chemipulse III portable electroporator (EU patent application number 2221086) and delivered by means of modified caliper electrodes with 1 cm distance between the plates until complete coverage of the lesion and 1 centimeter of margin (Figs 1–3). The pulse repetition frequency was 1 Hz and the frequency of burst repetition was 1 kHz. All of the ECT treatments were administered under general anesthesia using propofol at a dosage of 2 mg/kg after premedication with medetomidine at a dosage of 40 µg/kg and butorphanol at a dosage of 0.1 mg/kg. During the ECT treatments the cats were monitored using an electrocardiogram and a pulse oximeter.

### Table 1. World Health Organization TNM classification system for feline tumors of epidermal origin.

| Stage | Feature |
|-------|---------|
| T0    | No evidence of tumor |
| T1    | Tumor in situ |
| T2    | Tumor <2 cm diameter |
| T3    | Tumor 2–5 cm diameter or minimally invasive |
| T4    | Tumor >5 cm diameter or with invasion of subcutis such as fascia, muscle or bone |
| N0    | Absence of lymph node metastasis |
| N1    | Presence of lymph node metastasis |
| M0    | Absence of distant metastasis |
| M1    | Presence of distant metastasis |
Tumor Response Evaluation

Tumor measurements were recorded before initiation of treatment and before each treatment, and assessed as previously described. Although the VCOG RECIST system is the current method of tumor measurement in oncology, in this study tumor volume was calculated as (height × width × depth) × (π/6) for consistency with the current human and veterinary ECT literature. During the course of treatment, tumor measurements were made using calipers until remission or until relapse occurred and ultrasound examination was performed on large tumors to estimate their depth and margins. A complete remission (CR) was defined as total reduction in measured tumor volume and a partial remission (PR) as ≥50% reduction in tumor volume. Stable disease (SD) was defined as <50% reduction in tumor volume or <25% increase in tumor volume, and progressive disease (PD) was defined as ≥25% increase in tumor volume. A minimum duration of 2 weeks was required for a response to qualify as positive.

Fig 1. A 12-year-old female spayed cat with palpebral carcinoma. Patient at presentation (A), during an electrochemotherapy treatment (B) and at the completion of treatment consisting with 6 treatments (C and D).

Fig 2. (A) Advanced lip and buccal squamous cell carcinoma in a 12-year-old cat at presentation. (B) The cat was treated with systemic bleomycin at a dosage of 15 mg/m² followed by permeabilizing pulses. (C) The cat at the time of the third treatment. (D) After 5 treatments, the tumor went on to resolve completely. Adverse effects were limited to scratching.
Treatment Toxicity

Toxicity was defined as pathological events that occurred systemically in the cutaneous tissues within the treatment field or in the eye. Ocular examinations were done by 1 of the authors (MP) at time of inclusion in the study and before every ECT treatment, and included Schirmer tear test, biomicroscopy, fluorescein stain uptake, applanation tonometry and indirect ophthalmoscopy.

Possible adverse ocular effects were categorized as follows: adnexal disease (periocular alopecia, blepharitis or both), conjunctival disease (conjunctivitis), tear production $< 15$ mm/min or other lacrimal disorders, corneal disease (nonulcerative and ulcerative keratitis), lenticular disease (cataract development), uveal disease (iritis), and retinal disease (retinal atrophy). Acute adverse ocular effects were defined as clinical signs detected during or within the first 3 months after ECT treatment. Conversely, late adverse ocular effects were defined as clinical signs detected $\geq 3$ months after the last ECT treatment. Meanwhile, in the cohort of bulky carcinomas, local adverse effects to be evaluated included necrosis, fistula formation, scarring and cheloids, and distant adverse effects included tumor lysis syndrome and thromboembolism. Although late toxicities have been described for radiation therapy, this issue has not been clarified to date for ECT both in human and veterinary oncology, especially because limited information is available regarding possible damage inflicted by electric pulses to different ocular regions. One concern when working with ECT is the involuntary induction of cardiac arrhythmia and this concern warrants cardiac monitoring during ECT treatment. As a standard procedure, we monitor respiratory function at the same time for possible effects of ECT on anesthesia-induced respiratory depression.

Statistical Analysis

Response to treatment was assessed using the median time to terminal event and its 95% confidence interval. The terminal event was tumor progression, recurrence or death attributable to cancer or other noncancer causes. Time to recurrence was defined as the time from the observation of tumor disappearance and was estimated according to the Kaplan–Meier method. Statistical analysis for the relationship between tumor site (eyelids versus canthus or other cranial locations and T stage was performed using univariate analysis. The statistical significance of the differences in time to recurrence among the prognostic groups was evaluated by the log-rank test. P values $<.05$ were regarded as significant in 2-tailed tests. Commercial software was used for statistical analysis.

Results

A total of 47 domestic shorthair cats entered the study. In the periocular cohort, 21 cats were entered into the study, 12 received bleomycin with electroporation (7 T$_2$ stage and 5 T$_3$ stage) and 9 received bleomycin alone (5 T$_2$ stage and 4 T$_3$ stage) (see Table 1 for TNM classification). There were 7 female spayed and 5 male castrated in the ECT group and ages ranged from 9 to 13 years (median, 11.6), whereas in control group (bleomycin alone) there were 5 female spayed and 4 male castrated cats, and ages ranged from 7 to 13 years (median, 11.1). The advanced head SCC cohort had 26 cats. Fourteen cats received bleomycin coupled with electroporation (2 T$_2$ stage and 12 T$_3$ stage) and 9 received bleomycin alone (5 T$_2$ stage and 4 T$_3$ stage) (see Table 1 for TNM classification). There were 7 female spayed and 5 male castrated in the ECT group and ages ranged from 9 to 13 years (median, 11), whereas in control group (bleomycin alone) there were 5 female spayed and 4 male castrated cats, and ages ranged from 7 to 13 years (median, 11.2).

No cat had prior treatment or concurrent medications. The neoplastic lesions, accordingly to the owners, had been present from 9 to 15 months before referral.
**Toxicities**

**Local Toxicities.** Cats in the periocular ECT cohort did not show any evidence of corneal, uveal, or retinal damage. Tear production did not change over time, but in 3 cats treatment resulted in epiphora, suspicious for lacrimal duct sclerosis (Figs 1, 4, 5). The cats in the periocular bleomycin cohort did not experience local adverse effects. In the advanced head SCC ECT cohort, despite the use of electroconductive gel, 4 cats had small electrode-induced burns that resulted in 1 cm long, 1 mm wide discolored areas. These lesions tended to disappear within 2–3 weeks as previously reported. Cutaneous lesions were not reported in the controls. Two cats in the advanced head SCC ECT group had local inflammation involving the deep subcutaneous connective tissues, which led to compulsive scratching. In both cats the inflammation was successfully managed by administration of the non-steroidal anti-inflammatory drug meloxicam at a daily dosage of 0.05 mg/kg for a period of 1 week. All of the cats that underwent ECT experienced transient muscular contractions at the time of treatment, that were more pronounced in those cats with tumors located near nerve roots at the base of the skull. These contractions did not result in apparent pain or discomfort for the cats when they recovered from sedation and did not require symptomatic treatment.

**Systemic Toxicities.** As previously reported, neither cardiac arrhythmias nor respiratory treatment induced adverse effects were reported. In the ECT cohorts, patient oxygen saturation remained stable throughout the procedure. Hematological toxicity was not observed in the 26 cats of the ECT study, except for mild neutropenia on day 7 in 2 cats (grade I according to VCOG-CTAE guidelines). Gastrointestinal and renal toxicities were not detected. Toxicity was not observed in the bleomycin group.

**Response to Treatment**

The ECT groups had 2–9 treatments (median, 4), whereas the bleomycin group had 2–16 doses of bleomycin (median, 5). In the ECT groups 21/26 cats had CR (81%), 2 had a PR (7.5%) and 3 had PD (11.5%). In the bleomycin groups 4/21 patients achieved CR (19%), 3/21 had PR (14%), 6/21 had SD (29%) and 8/21 had PD (38%). Of the 26 cats enrolled in the ECT studies, 4 died of metastatic carcinoma to the lung after 4–7 months, approximately 1 month after lung metastases were detected, and 2 had tumor recurrence that was successfully retreated with additional ECT (2 and 3 treatments, respectively). The median time to progression for the pooled ECT groups was 30.5 months whereas in the bleomycin groups median time to progression was 3.9 months \((P < .0001)\). The median time to progression for the 2 ECT cohorts was 24.2 months for the periocular cohort and 20.6 months for the advanced head SCC cohort respectively. Figures 1–5 show 5 representative cases of response in cats with advanced disease. In the bleomycin group, all of the cats died or were euthanized as a result of tumor progression at different times (range 0–16 months) with a mean time for the periocular cohort of 4.7 months and a mean time for the advanced carcinoma cohort of 3.2 months. In the ECT cohort 4 cats were euthanized because of metastatic disease and 3 because of progres-

---

**Fig 4.** An 11-year-old male castrated cat with advanced periocular carcinoma. Patient at presentation (A), after 2 treatments of electrochemotherapy (ECT) (B), at the time of the 6th and last ECT (C) and at 1 month follow-up (D). The patient died of pulmonary metastases 5 months after completion of ECT.
sive disease. Statistical analysis failed to identify prognostic factors in the groups and there was no significant difference between the responses of the 2 ECT cohorts. Figure 6 shows the Kaplan–Meier curve of the 2 cohorts of cats (ECT treated versus bleomycin alone).

Discussion

To the best of our knowledge, ours is the first study of the application of biphasic pulse ECT in the treatment of cats with periocular carcinoma and advanced SCC of the head. The only other reports in the veterinary literature describe ECT for the treatment of nasal planum and superficial carcinoma with intralesional or systemic bleomycin. ECT was capable of achieving an overall response rate in 89% of the cats with acceptable adverse effects. Many reports have indicated that aggressive surgical excision or radiation therapy are the modalities that offer the highest chance of obtaining local control, but, tumor control and survival are highly dependent on reaching adequate surgical margins or on the degree of response to radiotherapy. Surgery often is limited by anatomical and functional considerations because treatment of periocular carcinoma can have major cosmetic and functional effects on the patient. Cats undergoing surgical or radiotherapy management may suffer adverse events ranging from trichiasis and secondary corneal disease to partial or total disfigurement and ocular toxoeses that may result in vision loss. In terms of efficacy, recent reports on the adoption of radiation therapy for facial and periocular carcinoma in cats reported median disease-free time of 414 days and mean disease-free time of 271 days, respectively. Identified prognostic factors for radiation therapy in these studies were low Ki 67 and tumor stage, respectively. In our study, ECT greatly improved the efficacy of bleomycin against advanced carcinoma. In fact, in our study, bleomycin alone resulted in inadequate tumor control, whereas ECT successfully induced tumor response in 21/26 cats with carcinoma. In our study, different cohorts of cats affected by solid tumors were treated with bleomycin with or without ECT allowing to clearly demonstration of the improved efficacy of chemotherapy after the application of permeabilizing electric pulses.

Bleomycin’s mechanism of tumor destruction derives from its ability to induce single- and double-strand DNA cleavage, thus mimicking radiation-induced DNA cleavage. Unfortunately, the efficacy of bleomycin is limited by its complex diffusion through the cell membrane’s lipid bilayer because it can only enter the cell through protein membrane carriers, thus resulting in slow and limited quantitative uptake under normal conditions. The lack of expression of these protein membrane carriers by tumor cells undergoing chemotherapy is the primary mechanism of cancer escape, making the degree and duration of tumor response unpredictable. On the other hand, in vitro and in vivo preclinical studies have shown that bleomycin’s uptake can be increased 700-fold after electroporation, resulting in massive apoptotic death of cancer cells. This effect ultimately results in increased local control after the application of permeabilizing electric pulses, although its efficacy to counter distant metastases still is limited. Preclinical and clinical
studies had shown a lack of anti-tumor efficacy of electric pulses in the absence of systemic or intra-lesional chemotherapy. Therefore, we did not include a control group treated with electroporation alone.30 We speculate that this might be a consequence of ECT-induced apoptotic death of tumor cells that might uncover hidden antigens and thus boost the immune response. The study has some limitations. The relatively low number of cats and lack of randomization were influenced by the willingness of some owners to pursue a more aggressive therapy based on emotional or financial reasons. However, the degree of local control is promising, considering the relatively low cost of treatment and few adverse effects observed in our study. These results make this treatment a potentially affordable alternative to more standardized therapeutic options. Another point to be considered is that 4 ECT-treated animals died of metastatic disease, indicating that additional chemotherapy agents might be beneficial in the treatment of this neoplasm. Additional studies with larger number of patients are warranted to fully elucidate the potential role of ECT for SCC in cats, especially considering the extended duration of local control and the preservation of the normal facial architecture in the ECT groups.

Footnotes
a Bleomicina Solfato, Sanofi-aventis, Milan, Italy
b Rapinovet, Intervet Italia, Milan, Italy
c Domitor, Pfizer Italia, Milan, Italy
d Dolorex, Intervet Italia, Milan, Italy
e SPSS Chicago, version 10.00, SPSS Inc., Chicago, IL

Acknowledgments
This work was partially supported by an INAIL Grant, by Grant 2011 of the Italian Ministry of Health to EPS and GS, and by a FUTURA-onlus Grant to EPS and AB and a Second University of Naples Grant to AB. This work was partially presented at the 2nd World Veterinary Cancer Congress held in Paris on March 2012. The authors thank Dr Andrea Pace (Roman Animal Clinic, Palm Beach, Florida) and Dr Guy Beretich for review of the manuscript.

Conflict of Interest Declaration: EPS and AB are among the applicants of the patent for the Chemipulse III portable electroporator (EU patent application number 2221086).

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References
1. Vilar-Saavedra P, Kitchell BE. Sunlight-induced skin cancer in companion animals. In: Baldi A, Pasquali P, Spugnini EP, eds. Skin Cancer, a Practical Approach. New York: Springer; 2014:499–514.
2. Sabatini S, Marconcato L, Zoff A, et al. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J Feline Med Surg 2010;12:760–768.
3. Miller MA, Nelson SL, Turk JR, et al. Cutaneous neoplasia in 340 cats. Vet Pathol 1991;28:389–395.
4. Hargis AMIP, Spangler WL, Stannard AA. A retrospective clinicopathologic study of 212 dogs with cutaneous hemangiosomas and hemangiosarcomas. Vet Pathol 1992;4:316–328.
5. Villanini JA, Henry CJ, Bryan JN, et al. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. J Am Vet Med Assoc 2011;239:960–965.
6. Pirie CG, Knollinger AM, Thomas CB, et al. Canine conjunctival hemangiomata and hemangiosarcoma: A retrospective evaluation of 108 cases (1989–2004). Vet Ophthalmol 2006;9:215–226.
7. Pirie CG, Dubielzig RR. Feline conjunctival hemangioma and hemangiosarcoma: A retrospective evaluation of eight cases (1993–2004). Vet Ophthalmol 2006;9:227–231.
8. Ratushn Y, Gober MD, Hick R, et al. From keratinocyte to cancer: The pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012;122:464–472.
9. Murphy S. Cutaneous squamous cell carcinoma in the cat: Current understanding and treatment approaches. J Feline Med Surg 2013;15:401–407.
10. Newkirk KM, Rohrbach BW. A retrospective study of eyelid tumors from 43 cats. Vet Pathol 2009;46:916–927.
11. Schmidt K, Bertani C, Martano M, et al. Reconstruction of the lower eyelid by third eyelid lateral advancement and local transposition cutaneous flap after “en bloc” resection of squamous cell carcinoma in 5 cats. Vet Surg 2005;34:78–82.
12. Clarke RE. Cryosurgical treatment of feline cutaneous squamous cell carcinoma. Aust Vet Pract 1991;21:148–153.
13. Medler K, Guscetti F, Rohrer Bley C, et al. Ki67 reactivity in nasal and periorcular squamous cell carcinomas in cats treated with electron beam radiation therapy. J Vet Intern Med 2006;20:676–681.
14. Pinard CL, Mutsaers AJ, Mayer MN, Woods JP. Retrospective study and review of ocular radiation side effects following external-beam Cobalt-60 radiation therapy in 37 dogs and 12 cats. Can Vet J 2012;53:1301–1307.
15. Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemotherapy by electroporation: Clinical experiences and perspectives of use of electrochemotherapy. Future Oncol 2014;10:877–890.
16. Spugnini EP, Baldi A, Electrochemotherapy in veterinary oncology: From rescue to first line therapy. Methods Mol Biol 2014;1121:247–256.
17. Spugnini EP, Vincenzi B, Citro G, et al. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: A preliminary report. Vet J 2009;179:117–120.
18. Spugnini EP, Baldi A, Vincenzi B, et al. Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: A preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol 2007;59:375–381.
19. Spugnini EP, Renaud SM, Bugliosi S, et al. Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: An approach to improve the therapeutic index of highly toxic chemotherapy drugs. J Transl Med 2011;9:152.
20. Tozon N, Pavlin D, Sersa G, et al. Electrochemotherapy with intravenous bleomycin injection: An observational study in superficial squamous cell carcinoma in cats. J Feline Med Surg 2014;16:291–299.
21. Spugnini EP, Porrello A. Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J Exp Clin Cancer Res 2003;22:571–580.
22. Salwa SP, Bourke MG, Forde PF, et al. Electrochemotherapy for the treatment of ocular basal cell carcinoma; a novel adjunct in the disease management. J Plast Reconstr Aesthet Surg 2014;67:403–406.

23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.

24. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: A critical review. Int J Radiat Oncol Biol Phys 2011;79:650–659.

25. Dotsinsky I, Nikolova B, Peycheva E, et al. New modality for electrochemotherapy of surface tumors. Biotechnol Biotechnol Eq 2012;26:3402–3406.

26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.

27. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1–39.

28. Cunha SC, Carvalho LA, Canary PC, et al. Radiation therapy for feline cutaneous squamous cell carcinoma using a hypofractionated protocol. J Feline Med Surg 2010;12:306–313.

29. Tounekti O, Pron G, Belchadek J Jr, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1995;53:5462–5469.

30. Daskalov I, Mudrov N, Peycheva E. Exploring new instrumentation parameters for electrochemotherapy. Attacking tumors with bursts of biphasic pulses instead of single pulses. IEEE Eng Med Biol 1999;18:62–66.